Selected article for: "regression analysis and risk factor"
Author: Zhichao Feng; Jennifer Li; Shanhu Yao; Qizhi Yu; Wenming Zhou; Xiaowen Mao; Huiling Li; Wendi Kang; Xin Ouyang; Ji Mei; Qiuhua Zeng; Jincai Liu; Xiaoqian Ma; Pengfei Rong; Wei Wang
Title: The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
  • Document date: 2020_4_10
    • ID: k65501xp_38
    Snippet: that older age and hypertension without ACEI/ARB therapy were independently associated with developing severe pneumonia in COVID-19. 2, 3, 22 The association between age and severe pneumonia may be attributed to the accumulation of medical comorbidities with age or decline in immune function over time. Given the close collinearity between age and hypertension, our study adjusted for age by multivariate regression analysis and revealed that hypert.....
    Document: that older age and hypertension without ACEI/ARB therapy were independently associated with developing severe pneumonia in COVID-19. 2, 3, 22 The association between age and severe pneumonia may be attributed to the accumulation of medical comorbidities with age or decline in immune function over time. Given the close collinearity between age and hypertension, our study adjusted for age by multivariate regression analysis and revealed that hypertension remained an independent risk factor for disease progression irrespective of age for patients without receiving ACEI/ARB therapy.

    Search related documents:
    Co phrase search for related documents
    • ACEI ARB therapy and disease progression: 1, 2, 3, 4
    • ACEI ARB therapy and hypertension age: 1, 2
    • ACEI ARB therapy and multivariate regression: 1, 2, 3, 4, 5
    • ACEI ARB therapy and multivariate regression analysis: 1, 2, 3, 4
    • age adjust and hypertension age: 1, 2
    • age adjust and multivariate regression: 1, 2, 3, 4, 5
    • age adjust and multivariate regression analysis: 1, 2, 3, 4
    • ARB therapy and disease progression: 1, 2, 3, 4, 5
    • ARB therapy and hypertension age: 1, 2, 3
    • ARB therapy and multivariate regression: 1, 2, 3, 4, 5, 6
    • ARB therapy and multivariate regression analysis: 1, 2, 3, 4
    • disease progression and hypertension age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease progression and hypertension old age: 1, 2, 3
    • disease progression and immune function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease progression and immune function decline: 1
    • disease progression and multivariate regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease progression and multivariate regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • hypertension age and immune function: 1, 2, 3, 4
    • hypertension age and multivariate regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25